跳至主要内容
临床试验/NCT00112892
NCT00112892已完成1 期

A Phase I and Pharmacokinetic Study of Selenomethionine With Fixed Dose Irinotecan in Advanced Solid Tumors

Roswell Park Cancer Institute2 个研究点 分布在 1 个国家目标入组 36 人开始时间: 2004年8月最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
已完成
入组人数
36
试验地点
2
主要终点
Maximum tolerated dose

研究概览

简要总结

RATIONALE: Drugs used in chemotherapy, such as irinotecan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Selenium may allow higher doses of irinotecan to be given. Giving irinotecan together with selenium may kill more tumor cells.

PURPOSE: This phase I trial is studying the side effects and best dose of selenium when given together with irinotecan in treating patients with advanced solid tumors.

详细描述

OBJECTIVES:

Primary

  • Determine the optimal loading and maintenance doses of selenium necessary to achieve selenium concentrations exceeding 15 μM when administered with irinotecan in patients with advanced solid tumors.

Secondary

  • Determine the pharmacokinetics of this regimen in these patients.
  • Determine the toxic effects of this regimen in these patients.
  • Determine any observed tumor response to this regimen in these patients.

研究设计

研究类型
Interventional
主要目的
Treatment

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

结局指标

主要结局

Maximum tolerated dose

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验